NAD+ (Injectable) — Half-Life, Dosing & Protocol Guide

Also known as: IV NAD+, NAD+ infusion, injectable nicotinamide adenine dinucleotide

Preclinical· Half-life from Grant et al., Front Aging Neurosci 2019, PMC675132

Plasma Half-Life

No formal human plasma t½ published

Source: Grant et al., Front Aging Neurosci 2019, PMC6751327

Route

Intravenous infusion / Subcutaneous

Frequency

2–3× weekly maintenance

Standard Dose

250–1000mg IV over 2–8h

Pharmacokinetics & Mechanism

Injectable NAD+ (nicotinamide adenine dinucleotide) has no formally published human plasma half-life. Grant et al. (2019, PMC6751327) demonstrated during a 6-hour IV infusion that plasma NAD+ levels only rise after ≥2 hours, suggesting rapid conversion to metabolites (NAAD, NMN, nicotinamide) before cellular uptake. The functional effects are mediated by these metabolites, not by intact NAD+ reaching cells directly.

⚠ No Published Human PK Data
Half-life values for this compound are based on preclinical (animal) studies or community estimates only. These cannot be assumed to apply to humans.

Track NAD+ (Injectable) in Halflife

The Halflife app tracks your NAD+ (Injectable) protocol with real-time concentration curves, dose logging, injection site rotation, and vial inventory — all on-device with no account required.

See your NAD+ (Injectable) curve live

Real-time concentration model based on your actual dose and injection time. Free iOS app.

Download on App Store